Anmelden Kostenlos registrieren

180 Life Sciences Zukünftige P/E

Was ist das Zukünftige P/E von 180 Life Sciences?

Zukünftige P/E von 180 Life Sciences Corp. ist 6.08

Was ist die Definition von Zukünftige P/E?



Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens für die nächsten zwölf Monate.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Zukünftige P/E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences

Was macht 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Unternehmen mit zukünftige p/e ähnlich 180 Life Sciences